NYSE · RMD

ResMed Inc.

$195.27 +$3.38 (+1.76%) 1D After hours
Charting by TradingView

Key Metrics

$27.83B
Market cap
18.32×
P/E · TTM
$5.54B
Revenue · TTM
$1.52B
Net income
EPS · TTM $10.38
Dividend yield 1.2%
Free cash flow $1.75B
Beta · 1Y 0.49
EBITDA · TTM $2.12B
Gross margin 61.6%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 2
    From its Feb 9 high, the share price fell 34%.

    Peak close $275.96 on Feb 9; trough close $182.82 on Jun 2. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -34%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$27.83B
Enterprise value$26.58B
Shares outstanding145.1M
52-wk range$180.27 – $293.81
Avg volume · 20D862.6K
Net cash $1.26B
Book value / share$44.35
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNYSE
About ResMed Inc.
IPO dateJun 2, 1995
Employees10600

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E18.32
P/S5.03
P/FCF15.87
EV/EBITDA12.55
EV/Sales4.80
Graham №$101.79

Profitability

Gross 61.6%
Operating 34.4%
Net 27.4%
FCF 31.7%
ROE / ROIC 26.8% · 29.0%

Financial Health

Current ratio3.01
Quick ratio2.33
Debt / equity0.06
Debt / EBITDA 0.19Low leverage
Net cash $1.26B
Working capital$2.71B

Cash Flow · TTM

Operating CF $1.89B
Capex −$135.74M
Free cash flow $1.75B
Buybacks $600.05M
Dividends paid $340.16M
Shareholder yield 3.4%

Piotroski F-Score

7 / 9
Strong fundamentals · 7 of 9 signals passing

Altman Z-Score

10.1
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$101.79 vs $195.27
Trades 1.9× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings